Back to stock research

Source-verified risk research

Research updated: Jul 12, 2026, 12:00 AM UTC

ABT Risks and Monitoring

Abbott Laboratories operates in Health Care Equipment within the health care sector. This profile tracks its company-specific earnings drivers, valuation conditions, and primary-source risks.

Company-specific risks

01

Nutrition weakness

Nutrition sales declined in the quarter, and persistent weakness could offset strength in medical devices and established pharmaceuticals.

Abbott Laboratories: Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences
02

Exact Sciences integration

The large Exact Sciences transaction introduces integration, financing, dilution, and execution risks before projected strategic benefits are realized.

U.S. Securities and Exchange Commission: Abbott Form 10-Q for the Quarter Ended March 31, 2026
03

Infant-formula litigation

Ongoing preterm infant formula litigation creates uncertain legal costs and potential reputational pressure for the nutrition business.

U.S. Securities and Exchange Commission: Abbott Form 10-Q for the Quarter Ended March 31, 2026

Thesis invalidation conditions

  • Reassess the thesis if nutrition sales declined in the quarter, and persistent weakness could offset strength in medical devices and established pharmaceuticals.

Related research

Full stock researchBSX peer researchISRG peer research

All verified sources

Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact SciencesAbbott Laboratories · earningsVerified

Fetched: 7/12/2026, 12:00:00 AM UTC

Published: 4/16/2026, 12:00:00 AM

Open original source
Abbott Investor RelationsAbbott Laboratories · companyVerified

Fetched: 7/12/2026, 12:00:00 AM UTC

Open original source
Abbott Form 10-Q for the Quarter Ended March 31, 2026U.S. Securities and Exchange Commission · filingVerified

Fetched: 7/12/2026, 12:00:00 AM UTC

Open original source